Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04917042 · ClinicalTrials.gov registry record · Phase 2
Tazemetostat in Malignant Peripheral Nerve Sheath Tumors
A Phase 2 study of Peripheral Nerve Sheath Tumor, sponsored by University of Florida.
- Active
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04917042 is a Phase 2 study of Peripheral Nerve Sheath Tumor that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04917042, a Phase 2 study of Peripheral Nerve Sheath Tumor, is active but no longer recruiting, sponsored by University of Florida.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath tumors.
Conditions Studied
Interventions
- DRUG Tazemetostat
Study Locations (1)
Florida
- University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-08-25 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04917042
The ClinicalTrials.gov registry entry for NCT04917042 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripheral Nerve Sheath Tumor appearing as the primary indexed condition, and to 1 intervention - of which Tazemetostat is the first listed.
NCT04917042 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04917042 about?
NCT04917042 is a clinical study titled "Tazemetostat in Malignant Peripheral Nerve Sheath Tumors". This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath tumors.
What is the current status of trial NCT04917042?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2021-08-25. Estimated completion is 2026-04.
What conditions does trial NCT04917042 study?
This clinical trial studies the following conditions: Peripheral Nerve Sheath Tumor.
What interventions are being tested in trial NCT04917042?
The interventions under investigation include: Tazemetostat (DRUG).
Who is sponsoring clinical trial NCT04917042?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04917042 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.